President Donald Trump’s Dec. 18 executive order directing the Justice Department to officially classify cannabis as a less-dangerous drug with medicinal value under federal law is historic and transformative.
But marijuana rescheduling is also generating confusion, wild speculation and genuine misinformation in and around the $32 billion U.S. regulated cannabis industry.
ADVERTISEMENT
On top of the practical questions, such as what exactly this does and when it happens, some wild theories and strange conjecture abound, including allegations this is all a looming Big Pharma takeover (not anytime soon) and that this means cannabis companies can claim federal tax relief going back years (don’t push your luck).
MJBizDaily participated in a webinar with Denver-based law firm Vicente LLP on Dec. 22 addressing these and a
Read full article on Marijuana Business Daily
